ocrelizumab (Rx)

Brand and Other Names:Ocrevus
  • Print

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

solution for injection

  • 30mg/mL (300mg/10mL single-dose vial)

Multiple Sclerosis

Indicated for adults with relapsing or primary progressive forms of multiple sclerosis

Initial 2 doses: 300 mg IV once; repeat this dose 2 wk later

Subsequent doses: 600 mg IV every 6 months

Also see Administration for instructions regarding premedication, dose dilution, infusion rate, and missed doses

Dosage Modifications

Infusion reactions

  • Dose modifications in response to infusion reactions depends on the severity
  • Life-threatening
    • Immediately stop and permanently discontinue ocrelizumab if there are signs of a life-threatening or disabling infusion reaction
  • Severe
    • Immediately interrupt the infusion and administer appropriate supportive treatment, as necessary
    • Restart the infusion only after all symptoms have resolved
    • When restarting, begin at half of the infusion rate at the time of onset of the infusion reaction
    • If this rate is tolerated, may increase the rate (see Administration)
  • Mild-to-moderate
    • Reduce the infusion rate to half the rate at the onset of the infusion reaction and maintain the reduced rate for at least 30 min
    • If this rate is tolerated, may increase the rate (see Administration)

Dosing Considerations

HBV screening

  • Perform Hepatitis B virus (HBV) screening before initiating ocrelizumab
  • Contraindicated with active HBV infection confirmed by positive results for HBsAg and anti-HBV tests
  • For patients who are negative for surface antigen [HBsAg] and positive for HB core antibody [HBcAb+] or are carriers of HBV [HBsAg+], consult liver disease experts before starting and during treatment

Vaccinations

  • Vaccination with live-attenuated or live vaccines is not recommended during treatment and after discontinuation until B-cell repletion
  • Administer all necessary immunizations according to immunization guidelines at least 6 weeks before initiating ocrelizumab

Safety and efficacy not established

Next:

Interactions

Interaction Checker

and ocrelizumab

No Results

     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            All Interactions Sort By:
             activity indicator 
            Previous
            Next:

            Adverse Effects

            >10%

            Upper respiratory tract infections (40-49%)

            Infusion-related reactions (34-40%)

            Skin infections (14%)

            Decreased neutrophil counts (13%)

            1-10%

            Lower respiratory tract infections (8-10%)

            Depression (8%) Cough (7%)

            Back pain (6%)

            Herpes virus-associated infections (5-6%)

            Diarrhea (6%)

            Peripheral edema (6%)

            Pain in extremity (5%)

            Previous
            Next:

            Warnings

            Contraindications

            Active HBV infection

            History of life-threatening infusion reaction to ocrelizumab

            Cautions

            Can cause infusion reactions that include pruritus, rash, urticaria, erythema, bronchospasm, throat irritation, oropharyngeal pain, dyspnea, pharyngeal or laryngeal edema, flushing, hypotension, pyrexia, fatigue, headache, dizziness, nausea, and tachycardia; monitor for reaction during the infusion and for at least 1 hr; permanently discontinue for a life-threatening reaction (also see Dosage Modifications and Administration)

            May increase risk for malignancy

            Infections

            • In clinical trials, a higher proportion of ocrelizumab-treated patients experienced infections (eg, respiratory tract, herpes) compared with interferon-beta1a or placebo
            • HBV reactivation: Fulminant hepatitis, hepatic failure, and death caused by HBV reactivation have occurred in patients treated with other anti-CD20 antibodies
            • Progressive multifocal leukoencephalopathy (PML)
              • PML is an opportunistic viral infection of the brain caused by the John Cunningham (JC) virus
              • PML has been observed in patients treated with other anti-CD20 antibodies and other multiple sclerosis therapies and has also been associated with some risk factors (eg, immunocompromised patients, polytherapy with immunosuppressants)
              • At the first sign or symptom suggestive of PML, withhold drug and perform an appropriate diagnostic evaluation
              • MRI findings may be apparent before clinical signs or symptoms

            Drug interaction overview

            • Coadministration with immunosuppressants may increase risk for immunosuppressive effects
            • Vaccination with live or live-attenuated vaccines is not recommended during ocrelizumab treatment and until B-cell repletion; administer all immunizations according to guidelines at least 6 wk before starting ocrelizumab
            Previous
            Next:

            Pregnancy

            Pregnancy

            No data available to assess risk in pregnant women

            However, transient peripheral B-cell depletion and lymphocytopenia have been reported in infants born to mothers exposed to other anti-CD20 antibodies during pregnancy

            Contraception

            • Women of childbearing potential should use contraception while receiving ocrelizumab and for 6 months after the last infusion

            Lactation

            Unknown if distributed in human breast milk

            Consider the developmental and health benefits of breastfeeding along with the mother’s clinical need for the drug, and any potential adverse effects on the breastfed infant from the drug or from the underlying maternal condition

            Pregnancy Categories

            A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

            B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

            C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

            D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

            X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

            NA:Information not available.

            more...
            Previous
            Next:

            Pharmacology

            Mechanism of Action

            Humanized monoclonal antibody designed to selectively target CD20, a cell surface antigen present on pre-B and mature B lymphocytes

            Following cell surface binding to B lymphocytes, ocrelizumab results in antibody-dependent cellular cytolysis and complement-mediated lysis

            Absorption

            Peak plasma concentration: 212 mcg/mL (600 mg); 141 mcg/mL (300 mg)

            AUC: 3510 mcg·mL/day

            Distribution

            Vd

            • Central volume distribution: 2.78 L
            • Peripheral volume compartment: 2.68 L/day
            • Intercompartment: 0.29 L/day

            Elimination

            Terminal half-life: 26 days

            Constant clearance: 0.17 L/day

            Initial time-dependent clearance: 0.05 L/day (declines with a half-life of 33 wk)

            Previous
            Next:

            Administration

            IV Compatibilities

            0.9% NaCl

            Polyvinyl chloride (PVC) bags and IV sets

            Polyolefin (PO) bags and IV sets

            IV Preparation

            Visually inspect vial for particulate matter and discoloration; do not use if solution is discolored or contains discrete foreign particulate matter

            Do not shake vial

            Using aseptic technique, withdraw dose and further dilute into 0.9% NaCl infusion bag to final concentration of ~1.2 mg/mL (ie, 300 mg in 250-mL bag, 600 mg in 500-mL bag)

            Product contains no preservative and is intended for single use only

            Before starting the IV infusion, the content of the infusion bag should be at room temperature

            Use the prepared infusion solution immediately or refrigerate (see Storage)

            IV Administration

            Administer the diluted infusion solution through a dedicated line using an infusion set with a 0.2 or 0.22 micron inline filter

            Observe patient for infusion reactions during the infusion and for at least 1 hr after completion of the infusion; inform patients that infusion reactions can occur up to 24 hr after the infusion

            See Dosage Modifications for instructions if infusion reaction occurs

            Infection assessment

            • Before every infusion, determine whether there is an active infection
            • In case of active infection, delay infusion until the infection resolves

            Premedication

            • Methylprednisolone 100 mg IV (or an equivalent corticosteroid): Premedicate ~30 min before each ocrelizumab infusion to reduce the frequency and severity of infusion reactions
            • Antihistamine (eg, diphenhydramine): Premedicate ~30-60 min before each ocrelizumab infusion to further reduce the frequency and severity of infusion reactions
            • Antipyretic (eg, acetaminophen): Addition to the above medications may be considered

            Infusion rate

            • Initial dose (first 2 IV infusions)
              • Dilute 300 mg in 250 mL 0.9% NaCl to final concentration of ~1.2 mg/mL
              • Start IV at 30 mL/hr
              • Increase by 30 mL/hr q30min
              • Maximum rate: 180 mL/hr
              • Infusion duration: ≥2.5 hr
            • Subsequent doses
              • Dilute 600 mg in 500 mL 0.9% NaCl to final concentration of ~1.2 mg/mL
              • Start IV at 40 mL/hr
              • Increase by 40 mL/hr q30min
              • Maximum rate: 200 mL/hr
              • Infusion duration: ≥3.5 hr

            Delayed or missed dose

            • If a planned infusion is missed, administer as soon as possible; do not wait until the next scheduled dose
            • Reset the dose schedule to administer the next sequential dose 6 months after the missed dose is administered
            • Doses must be separated by at least 5 months

            Storage

            Unopened vials

            • Refrigerate at 2-8°C (36-46°F) in the outer carton to protect from light
            • Do not freeze
            • Do not shake

            Diluted solution

            • Refrigerated at 2-8°C (36-46°F): Up to 24 hr
            • Room temperature up to 25°C (77°F): 8 hr (including infusion time)
            • In the event an IV infusion cannot be completed the same day, discard the remaining solution
            Previous
            Next:

            Images

            Previous
            Next:

            Formulary

            FormularyPatient Discounts

            Adding plans allows you to compare formulary status to other drugs in the same class.

            To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

            Adding plans allows you to:

            • View the formulary and any restrictions for each plan.
            • Manage and view all your plans together – even plans in different states.
            • Compare formulary status to other drugs in the same class.
            • Access your plan list on any device – mobile or desktop.

            The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

            Tier Description
            1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
            2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
            3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
            4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            NC NOT COVERED – Drugs that are not covered by the plan.
            Code Definition
            PA Prior Authorization
            Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
            QL Quantity Limits
            Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
            ST Step Therapy
            Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
            OR Other Restrictions
            Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
            Additional Offers
            Email to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Email Forms to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Previous